These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6797388)

  • 21. Abnormalities in the regulation of prolactin in patients on maintenance hemodialysis.
    Leu ML; Huang HS; Huang BY; Huang CC
    Taiwan Yi Xue Hui Za Zhi; 1985 Sep; 84(9):1059-70. PubMed ID: 3937888
    [No Abstract]   [Full Text] [Related]  

  • 22. Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet).
    Goetz CG; Tanner CM; Klawans HL; Shannon KM; Carroll VS
    Neurology; 1987 May; 37(5):875-8. PubMed ID: 3574696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dyskinesias in levodopa-carbidopa intestinal gel infusion era: New challenges, new features.
    Catalán MJ; Escribano PM; Alonso-Frech F
    Mov Disord; 2017 Apr; 32(4):624-625. PubMed ID: 28116835
    [No Abstract]   [Full Text] [Related]  

  • 24. 24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.
    Ricciardi L; Bove F; Espay KJ; Lena F; Modugno N; Poon YY; Krikorian R; Espay AJ; Fasano A
    Mov Disord; 2016 Apr; 31(4):597-8. PubMed ID: 26946221
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M; Leinonen M; Poewe W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypothalamic dysfunction in Parkinson's disease patients.
    Otake K; Oiso Y; Mitsuma T; Hirooka Y; Adachi K
    Acta Med Hung; 1994; 50(1-2):3-13. PubMed ID: 7638039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Drug therapy of Parkinson's disease].
    Zhou XD
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):193-6. PubMed ID: 4075905
    [No Abstract]   [Full Text] [Related]  

  • 28. Response to Sinemet 25/100 in Parkinson's disease.
    Ulm G; Gerdes U; Lehmann K
    Adv Neurol; 1984; 40():541-7. PubMed ID: 6695634
    [No Abstract]   [Full Text] [Related]  

  • 29. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
    Cedarbaum JM; Kutt H; McDowell FH
    Neurology; 1989 Nov; 39(11 Suppl 2):38-44; discussion 59. PubMed ID: 2586762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dissociation of thyrotropin and prolactin responsiveness to thyrotropin releasing hormone stimulation in L-dopa treated parkinsonian patients.
    Rabey JM; Vardi Y; Ravid R; Ayalon D
    Horm Res; 1981; 15(2):78-87. PubMed ID: 6799381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ultrasensitive TSH assay and anti-parkinsonian treatment with levodopa.
    Vergès B; Giroud M; Vaillant G; Verges-Patois B; Brun JM; Putelat R
    J Neurol Neurosurg Psychiatry; 1992 Dec; 55(12):1210-1. PubMed ID: 1479407
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
    Antonini A; Fung VS; Boyd JT; Slevin JT; Hall C; Chatamra K; Eaton S; Benesh JA
    Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
    Hauser RA; Ellenbogen AL; Metman LV; Hsu A; O'Connell MJ; Modi NB; Yao HM; Kell SH; Gupta SK
    Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of prostaglandin inhibitors on pituitary and thyroid responses to thyrotropin-releasing hormone in man: PGs and pituitary-thyroid system.
    Pasargiklian E; De Rosa G; Troncone L; Modugno I; Satta MA; Maussier M
    Adv Prostaglandin Thromboxane Res; 1980; 8():1303-8. PubMed ID: 6769310
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alleviation of severe emotional symptoms by carbidopa-levodopa, MSD, in a Parkinson's patient: a personal report.
    Doe J
    J Nerv Ment Dis; 1987 Mar; 175(3):185-6. PubMed ID: 3819716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Carbidopa-levodopa, growth hormone and parkinsonism].
    Marti-Masso JF; Carrera N; Martínez-Lage JM
    Rev Clin Esp; 1976 Jun; 141(6):525-32. PubMed ID: 968087
    [No Abstract]   [Full Text] [Related]  

  • 38. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Breck L; Kutt H; McDowell FH
    Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
    Senek M; Nielsen EI; Nyholm D
    Mov Disord; 2017 Feb; 32(2):283-286. PubMed ID: 27987231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
    Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.